Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Chief Medical Officer | August 12, 2020 | August 14, 2020 |
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Director | June 20, 2024 | June 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDOLOGIX INC /DE/
Report date August 12, 2020 · Filed August 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,878 |
Reported balance
After 2020-08-12 transaction · row 1
1 source rowRow 1 · 2020-08-12 · Sale · Disposed 21,888 · Balance 52,878 |
Vivos Therapeutics, Inc.
Report date June 20, 2024 · Filed June 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2029-06-20 | Direct | 7,067 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 4,000 · Balance 7,067 F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 28, 2024 20:53 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 4,000 | $2.38 Strike: $2.38 | $9,520.00 |
DisclosureSEC source: 0001493152-24-025692 · ownership.xml · derivative · entry 1 Thompson Matthew · CIK 0001740988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,067 Underlying: Common Stock · 4,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.48 Strike: $0.48 | $14,400.00 |
DisclosureSEC source: 0001493152-22-036725 · ownership.xml · derivative · entry 1 Thompson Matthew · CIK 0001740988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,667 Underlying: Common Stock · 76,667 shares Expires 2027-12-23 F1 · derivative.exercise_date: 30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023. Read SEC document |
| August 05, 2021 Filed Aug 10, 2021 21:49 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $2.72 Strike: $2.72 | $81,600.00 |
DisclosureSEC source: 0001493152-21-019258 · ownership.xml · derivative · entry 1 Thompson Matthew · CIK 0001740988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,667 shares Expires 2026-08-05 F1 · derivative.exercise_date: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 18:47 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | SaleCommon Stock | 21,888 | $0.09 | $1,926.14 |
DisclosureSEC source: 0001013606-20-000167 · wf-form4_159744525010993.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,878 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 20:09 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerCommon Stock | 3,417 | $0.07 | $238.51 |
DisclosureSEC source: 0001013606-20-000144 · wf-form4_159684534736856.xml · nonDerivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,766 F2 · shares: Shares withheld on August 5, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on August 5, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 20:09 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerCommon Stock | 30,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-20-000144 · wf-form4_159684534736856.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,183 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on August 6, 2019. One-third of the shares subject to this restricted stock unit award vested pursuant to the terms of this award. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:04 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 783 | $1.00 | $783.00 |
DisclosureSEC source: 0001013606-20-000013 · wf-form4_158085027328404.xml · nonDerivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,183 F2 · shares: Shares withheld on January 31, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on January 31, 2020. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:04 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 1,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-20-000013 · wf-form4_158085027328404.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,966 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on February 1, 2019. 100% of the shares subject to this restricted stock unit award vested pursuant to the terms of this award. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 16:20 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 5,278 | $1.68 | $8,867.04 |
DisclosureSEC source: 0001013606-20-000006 · wf-form4_157800002042354.xml · nonDerivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,966 F2 · shares: Shares withheld on December 30, 2019 to satisfy statutory minimum tax withholding obligations related to shares vested on December 30, 2019. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 16:20 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 47,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-20-000006 · wf-form4_157800002042354.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,244 F1 · shares: This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on January 2, 2019. One third of the shares subject to this restricted stock unit award vested pursuant to the terms of this award. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 6,304 | Not disclosed Strike: $4.71 | Not disclosed |
DisclosureSEC source: 0001013606-19-000169 · wf-form4_156996180819122.xml · derivative · entry 3 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,304 Underlying: Common Stock · 6,304 shares Expires 2026-09-10 F4 · shares: The options vest in three equal annual installments over a three-year period commencing on September 10, 2019. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 8,999 shares of common stock granted to the reporting person on May 31, 2017, and (ii) an option for 9,907 shares of common stock granted to the reporting person on December 1, 2016. In exchange, the reporting person received a new stock option, for 6,304 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 9,907 | Not disclosed Strike: $69.10 | Not disclosed |
DisclosureSEC source: 0001013606-19-000169 · wf-form4_156996180819122.xml · derivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,907 shares Expires 2026-12-01 F3 · shares: Twenty-five percent of the options vested upon one year of service and the remaining balance continued to vest in equal monthly installments thereafter. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 8,999 shares of common stock granted to the reporting person on May 31, 2017, and (ii) an option for 9,907 shares of common stock granted to the reporting person on December 1, 2016. In exchange, the reporting person received a new stock option, for 6,304 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 16:30 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerOption to Purchase · Derivative | 8,999 | Not disclosed Strike: $48.20 | Not disclosed |
DisclosureSEC source: 0001013606-19-000169 · wf-form4_156996180819122.xml · derivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,999 shares Expires 2027-05-31 F1 · shares: Options vest ratably over forty-eight months. F2 · price: The issuer cancelled, pursuant to the issuer's option exchange program which expired on September 9, 2019, (i) an option for 8,999 shares of common stock granted to the reporting person on May 31, 2017, and (ii) an option for 9,907 shares of common stock granted to the reporting person on December 1, 2016. In exchange, the reporting person received a new stock option, for 6,304 shares, having an exercise price of $4.71 per share, which is equal to the closing price per share of the common stock on the NASDAQ Global Market on September 10, 2019. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 17:15 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 60,867 | $6.67 Strike: $6.67 | $405,982.89 |
DisclosureSEC source: 0001013606-19-000132 · wf-form4_156512611903617.xml · derivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,867 Underlying: Common Stock · 60,867 shares Expires 2029-08-05 F2 · shares: Options vest ratably over thirty-six months. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 17:15 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 30,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000132 · wf-form4_156512611903617.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,244 F1 · shares: Performance restricted stock unit award based on predetermined goals. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:50 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 421 | $6.40 | $2,694.40 |
DisclosureSEC source: 0001013606-19-000094 · wf-form4_155752498602058.xml · nonDerivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,811 F2 · shares: Shares withheld on May 8, 2019 to satisfy statutory minimum tax withholding obligations related to shares vested on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:50 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000094 · wf-form4_155752498602058.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,232 F1 · shares: This award was originally reported on a Form 3 filed with the Securities and Exchange Commission on June 1, 2018. 50% of the shares subject to this restricted stock award vested pursuant to the terms of this award. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:03 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 19,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000029 · wf-form4_154905501691166.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,319 F1 · shares: 100% of the time-based restricted stock unit award shall vest on January 31, 2020 and shall settle in shares of common stock. Read SEC document |
| December 30, 2018 Filed Jan 2, 2019 21:03 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantOption to Purchase · Derivative | 225,621 | $0.74 Strike: $0.74 | $167,974.83 |
DisclosureSEC source: 0001013606-19-000022 · wf-form4_154648099216564.xml · derivative · entry 3 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,621 Underlying: Common Stock · 225,621 shares Expires 2028-12-30 F3 · shares: 100% of the option award shall vest on December 30, 2019. Read SEC document |
| December 30, 2018 Filed Jan 2, 2019 21:03 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 470,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000022 · wf-form4_154648099216564.xml · nonDerivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,177 F2 · shares: The time-based restricted stock unit award shall vest in three equal annual installments on December 30, 2019, December 30, 2020 and December 30, 2021 and shall settle in shares of common stock on each of those dates. Read SEC document |
| December 30, 2018 Filed Jan 2, 2019 21:03 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Disposition to issuerCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000022 · wf-form4_154648099216564.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,062 F1 · shares: Shares subject to this Form 4 were granted as part of a performance restricted stock unit granted May 31, 2017. All shares granted were forfeited as of March 13, 2018 due to the single performance milestone being deemed not achievable by the Company. This forfeiture was not previously reported to the Securities and Exchange Commission, as the number of shares was deemed immaterial by the issuer. Read SEC document |
| May 15, 2018 Filed Jun 1, 2018 20:13 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | Tax withholdingCommon Stock | 10,719 | $4.87 | $52,201.53 |
DisclosureSEC source: 0001013606-18-000089 · wf-form4_152789841822583.xml · nonDerivative · entry 2 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,692 F3 · shares: Shares withheld on May 15, 2018 to satisfy statutory minimum tax withholding obligations related to shares vested on May 15, 2018. Read SEC document |
| May 15, 2018 Filed Jun 1, 2018 20:13 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-18-000089 · wf-form4_152789841822583.xml · nonDerivative · entry 1 Thompson Matthew · CIK 0001740988 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,411 F1 · shares: This award was originally granted on June 15, 2015. 100% of the shares subject to this restricted stock award vested pursuant to the terms of this award. F2 · balance_after: Total shares owned includes 4,488 shares purchased through the Company's Employee Stock Purchase Plan on April 30, 2018 and have not previously been disclosed due to immateriality. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.